20亿元脑血管病药物,国内药企正扎堆递交仿制申请

动脉网
Jan 22

石药集团递交依达拉奉右莰醇注射用浓溶液仿制药上市申请,该药为先声药业自主研发的1类创新药,用于改善急性缺血性脑卒中症状,自2020年获批上市后销售额持续增长,且一直被纳入国家医保目录。随着其核心专利2029年到期,自2025年起大批国内药企扎堆申报仿制,目前已有12家企业加入竞争,但尚无企业成功获批,显示存在技术或法律壁垒。先声药业则通过专利布局加固、剂型创新延展、专利诉讼防御、市场与海外卡位四大...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10